Yuichi Iida
Overview
Explore the profile of Yuichi Iida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iida Y, Harada M
J Immunother Cancer
. 2024 Dec;
12(12).
PMID: 39672553
Background: Immune checkpoint blockade is a promising anticancer therapy, whereas the presence of T cells in tumor sites is indispensable for its therapeutic efficacy. To promote the infiltration of T...
2.
Oshimura M, Tabata T, Uno N, Takata S, Hichiwa G, Kanazawa I, et al.
Sci Rep
. 2024 Oct;
14(1):23623.
PMID: 39384966
Human mesenchymal stem cells (hMSCs) with extended lifespan and differentiation potential that can recapitulate in vivo characteristics could significantly contribute to basic research, drug development, and cell therapy. Specifically, they...
3.
Kotani H, Han W, Iida Y, Tanino R, Katakawa K, Okimoto T, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199555
Background: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). Aim: We determined whether axitinib could...
4.
Liu Y, Wai A, Zolzaya T, Iida Y, Okada S, Iizasa H, et al.
Virology
. 2024 Jul;
597:110161.
PMID: 38981317
Epstein-Barr virus (EBV) is linked to lymphoma and epithelioma but lacks drugs specifically targeting EBV-positive tumors. BamHI A Rightward Transcript (BART) miRNAs are expressed in all EBV-positive tumors, suppressing both...
5.
Hoque M, Iida Y, Kotani H, Harada M
Cancer Rep (Hoboken)
. 2024 Apr;
7(4):e2075.
PMID: 38662379
Introduction: Gemcitabine (GEM) is often used to treat pancreatic cancer. Many anti-cancer drugs induce cancer cell death, but some cells survive after cell cycle arrest. Such a response to DNA...
6.
Harada M, Kotani H, Iida Y, Tanino R, Minami T, Komohara Y, et al.
Cancer Sci
. 2024 Feb;
115(5):1405-1416.
PMID: 38413363
Hypoxia is a common feature of solid tumors. However, the impact of hypoxia on immune cells within tumor environments remains underexplored. Carbonic anhydrase 9 (CA9) is a hypoxia-responsive tumor-associated enzyme....
7.
Ishitobi K, Kotani H, Iida Y, Taniura T, Notsu Y, Tajima Y, et al.
Int Immunopharmacol
. 2022 Dec;
113(Pt A):109423.
PMID: 36461608
Myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are increased in cancer-bearing aged hosts. Arginase-I in MDSCs degrades L-arginine, an amino acid required for T cell activation and proliferation....
8.
Koyanagi A, Kotani H, Iida Y, Tanino R, Kartika I, Kishimoto K, et al.
Cell Prolif
. 2022 Sep;
55(12):e13326.
PMID: 36054146
Objective: Therapy-induced senescent cancer cells increase the expression of the cyclin-dependent kinase inhibitors p16 and p21 . Given that p21 regulates not only the cell cycle but also cell death,...
9.
Uehara S, Iida Y, Ida-Tanaka M, Goto M, Kawai K, Yamamoto M, et al.
Sci Rep
. 2022 Sep;
12(1):14907.
PMID: 36050438
Chimeric TK-NOG mice with a humanized liver (normal Hu-liver) are a unique animal model for predicting drug metabolism in humans. However, residual mouse hepatocytes occasionally prevent the precise evaluation of...
10.
Hoque M, Iida Y, Kotani H, Kartika I, Harada M
Anticancer Res
. 2022 Jul;
42(7):3495-3506.
PMID: 35790256
Background/aim: Anti-apoptotic proteins, including Bcl-2 and Bcl-xL, hinder cancer treatment, and several drugs targeting these molecules have been developed. One is ABT-263 (navitoclax), which targets Bcl-2, Bcl-xL, and Bcl-w. On...